Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069203
Filing Date
2025-05-12
Accepted
2025-05-12 16:10:30
Documents
75
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fgen-20250331.htm   iXBRL 10-Q 2551208
2 EX-10.1 fgen-ex10_1.htm EX-10.1 1215800
3 EX-10.2 fgen-ex10_2.htm EX-10.2 30683
4 EX-10.3 fgen-ex10_3.htm EX-10.3 30426
5 EX-10.4 fgen-ex10_4.htm EX-10.4 56180
6 EX-31.1 fgen-ex31_1.htm EX-31.1 10188
7 EX-31.2 fgen-ex31_2.htm EX-31.2 10182
8 EX-32.1 fgen-ex32_1.htm EX-32.1 10189
  Complete submission text file 0000950170-25-069203.txt   11757530

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fgen-20250331.xsd EX-101.SCH 1817786
77 EXTRACTED XBRL INSTANCE DOCUMENT fgen-20250331_htm.xml XML 1518910
Mailing Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133
Business Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133 415-978-1200
FIBROGEN INC (Filer) CIK: 0000921299 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36740 | Film No.: 25934899
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)